An exploratory analysis of the phase 2 ALYCANTE trial (NCT04531046) reveals that patients with relapsed/refractory large ...
C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation (R), highlighted the first use of its eMTBR-tau243 plasma assay in a Phase 3 dataset ...
Early PrimeC treatment slowed functional decline and reduced the risk of death or ALS complications for ALS patients in a ...
Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker 'MSLE” on Feb. 6 ...
Researchers led by Hiroki R. Ueda at the University of Tokyo developed comprehensive 3D cellular atlases spanning all organs ...
NDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated ...
Pooled analyses in patients with moderate Alzheimer’s show dose-related cognitive benefit and signs of durability.100% of patients remained ...
Cadence’s leadership in agentic AI is expanded by integrating portfolio of chip and system design solutions with NVIDIA’s ...
More than 80% of patients implanted with a transvenous phrenic nerve stimulation device for central sleep apnea had at least ...
On track to complete enrollment for the Phase 3 PROACT 1 accelerated approval analysis of rilparencel in mid-2026; anticipate pivotal topline ...
Good afternoon, ladies and gentlemen, and welcome to the Celcuity Fourth Quarter and Full Year 2025 Financial Call. [Operator Instructions] I would now like to turn the conference over to Jodi Sievers ...
GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results